Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

19.95
+0.06000.30%
Post-market: 19.950.00000.00%19:30 EDT
Volume:2.56M
Turnover:51.35M
Market Cap:3.44B
PE:9.09
High:20.24
Open:20.01
Low:19.88
Close:19.89
52wk High:30.96
52wk Low:19.59
Shares:172.31M
Float Shares:128.72M
Volume Ratio:0.84
T/O Rate:1.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.20
EPS(LYR):2.30
ROE:35.74%
ROA:3.64%
PB:2.63
PE(LYR):8.67

Loading ...

Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent

MT Newswires Live
·
Sep 29

Helix BioPharma Names Karen Krumeich Board Chair, Adds Three Directors

Reuters
·
Sep 29

Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, Extending U.S. Patent Protections to March 2041

THOMSON REUTERS
·
Sep 29

Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says

MT Newswires Live
·
Sep 26

Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says

MT Newswires Live
·
Sep 26

Deutsche Bank Lowers Price Target on ACADIA Pharmaceuticals to $31 From $38, Keeps Buy Rating

MT Newswires Live
·
Sep 25

BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Sep 25

Acadia Pharmaceuticals Inc. : Deutsche Bank Cuts Target Price to $31 from $38

THOMSON REUTERS
·
Sep 25

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Reuters
·
Sep 25

Acadia Pharmaceuticals Inc. : Oppenheimer Cuts Target Price to $23 from $25

THOMSON REUTERS
·
Sep 25

US Stocks on the MOVE-Charles River, Oracle, TD Synnex

Reuters
·
Sep 24

Acadia Pharmaceuticals Down over 8%, on Pace for Largest Percent Decrease Since September 2025

Dow Jones
·
Sep 24

Sector Update: Healthcare

MT Newswires Live
·
Sep 24

U.S. Stocks on the MOVE-Everpure, Dropbox, Darden Restaurants

Reuters
·
Sep 24

ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint

MT Newswires Live
·
Sep 24

Acadia Falls After Alzheimer's-Related Drug Narrowly Misses Goal in Study

Reuters
·
Sep 24

Acadia Pharmaceuticals Shares Fall 11.5% Premarket After Alzheimer's Related Experimental Drug Narrowly Misses Goal in Study

THOMSON REUTERS
·
Sep 24

Acadia Reports Phase 2 Radiant Topline Results for Remlifanserin in Alzheimer’s Disease Psychosis

Reuters
·
Sep 24

Acadia Pharmaceuticals - Remlifanserin Demonstrated Favorable Safety Profile with Adverse Event Rates Similar to Placebo

THOMSON REUTERS
·
Sep 24

Acadia Pharmaceuticals: to Continue Enrolling 2 Ongoing Phase 3 Studies Evaluating Remlifanserin in ADP, to Implement Amendments to Phase 3 Program

THOMSON REUTERS
·
Sep 24